Randy Dockens

Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease

Vladimir Coric, Christopher H. van Dyck, Stephen Salloway et al. · Archives of Neurology · 2012 · 369 citations

Medicine, Pharmacology, Pharmacotherapy +17

Targeting Prodromal Alzheimer Disease With Avagacestat

Vladimir Coric, Stephen Salloway, Christopher H. van Dyck et al. · JAMA Neurology · 2015 · 233 citations · Full text

Medicine, Neurology, Pharmacotherapy +17

Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder

Vladimir Coric, Howard Feldman, Dan A. Oren et al. · Depression and Anxiety · 2010 · 175 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome?

Seth Sweetser, Michael Camilleri, Sara J. Linker Nord et al. · American Journal of Physiology-Gastrointestinal and Liver Physiology · 2009 · 116 citations · Full text

Medicine, Endocrinology, Pharmacology +16

Anticonvulsant activity of some 4-aminobenzamides

Charles R. Clark, Martha J.M. Wells, Ricky T. Sansom et al. · Journal of Medicinal Chemistry · 1984 · 80 citations

Medicine, Medicinal Chemistry, Pharmacology +12